10 - The Michigan Daily - Thursday, March 10, 1994 Women's track aims for top four at NCAAs By DOUG STEVENS DAILY SPORTS WRITER For the Michigan women's track and field team, this season has been one of making goals and then suc- cessfully meeting them. Its first and primary goal was to win the Big Ten. The Wolverines achieved that two weeks ago. Then came Michigan's quest to qualify a significant number of women for the NCAA meet. It qualified ten team members, one of the largest con- tingents in the country. ~ This weekend, the team will strive to meet a third goal: finishing in the top four at the NCAA Champion- ships. U U 4&%k 215 S. Tn"pAnn ( u p P State St. Arbor DEAD stairs) -Aw" Michigan, which is heading into Indianapolis as the fourth seed, will need to score 30 to 32 points to come in fourth, according to assistant coach Mike McGuire. "People will have to come through," McGuire said. The Wolverines should be given a significant challenge from LSU, the two-time defending champions, as well as Texas and Alabama. Michigan should receive the bulk of its scoring from the distance run- ners. Molly McClimon, the winner of both the 3000 meters and 5000 meters at the Big Ten meet, is seeded second in the 5000 meters at NCAAs. She also is a member of the top-seeded distance medley relay team, Courtney Babcock, who was the victor in the mile at the Big Ten meet, will also be running the 5000 meters and distance medley relay. She is the third-seed in the 5000. Villanova's Jennifer Rhines is the top-seed. Both McClimon and Babcock also qualified for the NCAAs in the 3000 meters and the mile. "We are playing Russian Roulette if we stretch kids too far at nationals," McGuire responded when being asked about McClimon and Babcock not running the mile or 3000. "I am very happy with the events that I'm running." McClimon said. "I am just going to try to race as best as possible," The Wolverines' distance med- ley relay team is going into the NCAA Championships with the fast- est time in the country this season. The team is comprised of Babcock, McClimon, Richelle Webb and Kristine Westerby. Westerby will also be runningthe 800 meters, along with Jessica Kluge, the Big Ten; champion in that event. These two women are both poteitial scorers for Michigan. "I don't think Westerby andKluge have peaked yet," McGuire said. Other distance runners who will compete this weekend include Chris Szabo in the 3000 meters and Karen Harvey in the mile. In the high jump, Michigan will be represented by Linda Stuck and Monika Black, who finished second and third respectively, at the Big Ten meet. Tearza Johnson, who finished in third place in the conference, will run the 200 meters. "As a team, we have to get out and compete real hard, and let's see what happens when the dust clears," McGuire said. Darts + Dart Supplies \ Large selection Free Flights w/ every Purchase of Darts 44 Graduation: ...*** M This is your moment Ifyou have something to share with classmates,family, andfriends: Here is your opportunity Wanted: Student Speakers for the 1994 LS&A Spring Commencement (Fourth annual competition) Who: Open to all LS&A seniors eligible to graduate by the end of Winter Term 1994. What. Two students will each deliver a 2 minute commencement speech at the LS&A Spring Commencement on Saturday, April 30 at 12:00 noon in Michigan Stadium. When: The deadline for entries is Friday, March 11 at 5:00 pm. All speeches will be judged by the LS&A student commencement committee. Final selections will be made by Monday, March 28. Send typed texts to: LS&A Development and External Relations 350 South Thayer, Ann Arbor, MI 48104-1608 a Who ants, . all realy cool job " Id " I o! "Count me in!" The Michigan Daily is hiring! ted LiWill o sell ary. . SPORTS INFORMATION High jumper Monika Black will be one of the 10 members of the Michigan women's track and field team to compete at this weekend's NCAA meet. Department of Recreational Sports INTRAMURAL SPORTS PROGRAM WANTED! Broomball Officials Clinic Begins: Thursday 3/10 7:00 p.m. IMSB For Additional Information Contact IMSB 763-3562 The Display Department is looking for some highly students to join our sales team. As an Account Execu meet and communicate with Ann Arbor businesses it advertisements. Sales experience is helpful, but no Pick up an application at the Student PublicationsI Applications due today Y motival tive, you n order to t necessa Building. 420 Maynard I m mi I 14 ~ID~i.L I : Contraceptive Injection (sterile medroxyprogesterone acetate suspension, USP) WHAT IS DEPO-PROVERA CONTRACEPTIVE INJECTION? DEPO-PROVERA Contraceptive Injection is a form of birth control that is given as an intra- muscular injection (a shot) in the buttock or upper arm once every 3 months. To continue your contraceptive protection, you must return for your next injection promptly at the end of 3 months. DEPO-PROVERA contains medroxyprogesterone acetate, a chemical similar to (but not the same as) the natural hormone progesterone, which is produced by your ovaries during the second half of your menstrual cycle. DEPO-PROVERA acts by preventing your egg cells from ripening. If an egg is not released from the ovaries during your menstrual cycle, it cannot become fertilized by sperm and result in pregnancy. DEPO-PROVERA also causes changes in the lining of your uterus that make it less likely for pregnancy to occur. HOW EFFECTIVE IS DEPO-PROVERA CONTRACEPTIVE INJECTION? DEPO-PROVERA is over 99% effective, making it one of the most reliable methods of birth control available. This means that the average annual pregnancy rate is less than one for every 100 women who use DEPO-PROVERA. The effectiveness of most contraceptive methods depends in part on how reliably each woman uses the method. The effectiveness of DEPO-PROVERA depends only on the patient returning every 3 months for her next injection. Your health-care provider will help you compare DEPO-PROVERA with other con- traceptive methods and give you the information you need in order to decide which contra- ceptive method is the right choice for you. The following table shows the percent of women who got pregnant while using different kinds of contraceptive methods. It gives both the lowest expected rate of pregancy (the rate expected in women who use each method exactly as it should be used) and the typical rate of pregnancy (which includes women who became pregnant because they forgot to use their birth control or because they did not follow the directions exactly). PERCENT OF WOMEN EXPERIENCING AN ACCIDENTAL PREGNANCY IN THE FIRST YEAR OF CONTINUOUS USE Lowest Method Expected Typical DEPO-PROVERA 0.3 0.3 Implants (Norplant) 0.3 0.3 Female sterilization 0.2 0.4 Male sterilization 01 0.15 Oral contraceptive (pill) - 3 Combined 0.1- Progestogen only 0.5 - IUD- 3 Progestasert 2.0- Copper T 380A 0.8- Condom (without spermicide) 2 12 Diaphragm (with spermicide) 6 18 Cervical Cap 6 18 Withdrawal 4 18 Periodic abstinence 1 - 9 20 Spermicide alone 3 21 Vaginal Sponge Used before childbirth 6 18 Used after childbirth 9 28 No method 85 85 Source: Trussell et al; Obstet Gyncol 76:558,1990 WHO SHOULD NOT USE DEPO-PROVERA CONTRACEPTIVE INJECTION? Not all women should use DEPO-PROVERA. You should not use DEPO-PROVERA if you think you might be pregnant, have any vaginal bleeding without a known reason, have had cancer of the breast, have had a stroke, have or have had blood clots (phlebitis) in your legs, have problems with your liver or liver disease, or are allergic to DEPO- PROVEA (medroxyprogesterone acetate or any of its other ingredients). You will have a physical examination before your doctor prescribes DEPO-PROVERA. It is important to tell your doctor if you are taking any prescription or over-the-counter medications or if you have a family history of breast cancer; an abnormal mammogram (breast x-ray) fibrocystic breast disease, breast nodules or lumps, or bleeding from your npples; kidney disease; irregular or scanty menstrual periods; high blood pressure; migraine headaches; asthma; epilepsy (convulsions or seizures); diabetes or a family history of diabetes; or a hstoryof dress~ion. occur and, therefore, the bleeding that comes with your normal menstruation does not take place. When you stop using DEPO-PROVERA your menstrual period will usually, in time, return to its normal cycle. 2. Bone Mineral Changes Use of DEPO-PROV ERA may be associated with a decrease in the amount of mineral stored in your bones. This could increase your risk of developing bone fractures. The rate of bone mineral loss is greatest in the early years of DEPO-PROVERA use, but after that, it begins to resemble the normal rate of age-related bone mineral loss. 3. Cancer Studies of women who have used different forms of contraception found that women who used DEPO-PROVERA for contraception had no increased overall risk of developing cancer of the breast, ovary, uterus, cervix, or liver. However, women under 35 years of age whose first exposure to DEPO-PROVERA was within the previous 4 years may have a slightly increased risk of developing breast cancer similar to that seen with oral contraceptives. You should discuss this with your health-care provider. 4. Accidental Pregnancy Because DEPO-PRO VERA is such an effective contraceptive method, the risk of accidental pregnancy for women who get their shots regularly (every 3 months) is very low. While there have been reports of an increased risk of low birth weight and neonatal infant death or other health problems in infants conceived close to the time of injection, such pregnancies are rare. If you think you may have become pregnant while using DEPO-PROVERA for con- traception, see your health-care provider as soon as possible. 5. Other Risks Women who use hormone-based contraceptives may have an increased risk of blood clots or stroke. Also, if a contraceptive method fails, there is a possibility that the fertilized egg will begin to develop outside of the uterus (ectopic pregnancy). While these events are rare, you should tell your health-care provider if you have any of the problems listed in the next section. WHAT SYMPTOMS MAY SIGNAL PROBLEMS WHILE USING DEPO-PROVERA CONTRACEPTIVE INJECTION? Call your health-care provider immediately if any of these problems occur following an injection of DEPO-PROVERA: Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung); sudden severe headache or vomiting, dizzi- ness or fainting, problems with your eyesight or speech, weakness, or numbness in an arm or leg (indicating a possible stroke); severe pain or swelling in the calf (indicating a possible clot in the leg); unusually heavy vaginal bleeding; severe pain or tendemness in the lower abdominal area; or persistent pain, pus, or bleeding at the injection site.m WHAT ARE THE POSSIBLE SIDE EFFECTS OF DEPO-PROVERA CONTRACEPTIVE INJECTION? 1. Weight Gain You may experience a weight gain while you are using DEPO-PROVERA. About two thirds of the women who used DEPO-PROVERA in clinical trials reported a weight gain of about 5 pounds during the first year of use. You may continue to gain weight after the first year. Women in one large study who used DEPO-PROVERA for 2 years gained an average total of 8.1 pounds over those 2 years, or approximately 4 pounds per year. Women who contin- ued for 4 years gained an average total of 13.8 pounds over those 4 years, or approximate- ly 3.5 pounds per year. Women who continued for 6 years gained an average total of 16.5 pounds over those 6 years, or approximately 2.75 pounds per year. 2. Other Side Effects In a clinical study of over 3,900 women who used DEPO-PROVERA for up to 7 years, some women reported the following effects that may or may not have been related to their use of DEPO-PROVERA: Irregular menstrual bleeding, amenorrhea, headache, nervousness, abdominal cramps, dizziness, weakness or fatigue, decreased sexual desire, leg cramps, nausea, vaginal discharge or irritation, breast swelling and tenderness, bloating, swelling of the hands or feet, backache, depression, insomnia, acne, pelvic pain, no hair growth or excessive hair loss, rash, and hot flashes. Other problems were reported by veryfew of the women in the clinical trials, but some of these could be serious. These include convulsions, jaundice, urinary tract infections, allergic reactions, fainting, paralysis, osteoporosis, lack of return to fertility, deep vein thrombosis, pulmonary embolus, breast cancer, or cervical can- cer. If these or any other problems occur during your use of DEPO-PROVERA, discuss them with your health-care provider. SHOULD ANY PRECAUTIONS BE FOLLOWED DURING USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION? 1. Missed Periods During the time you are using DEPO-PROVERA for contraception, you may skip a period, or your periods may stop completely. If you have been receiving your DEPO-PROVERA injections regularly every 3 months, then you are probably not pregnant. However, if you think that you may be pregnant, see your health-care provider. 2. Laboratory Test Interactions f you are scheduled for any laboratory tests, tell your health-care provider that you are using DEPO-PROVERA for contraception. Certain blood tests are affected by hormones such as DEPO-PROVERA. 3. Drug Interactions Cytadren (aminoglutethimide) is an anticancer drug that. may significantlyidecrease the effecivenes of DEPO-PROVERA if the two drugs are given during the same'time. Take the best training program In the business a n- our MCAT Total Training includes dynamic class sessions, four testing sessions, our five-volume Home Study Notes, one-on-one unlimited tutoring, extra help sessions, and the unique resources of the Training Library, including Kaplan and AAMC practice tests. When you study with Kaplan, you get training and cross- ' I